Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Effects of ipriflavone on postmenopausal syndrome and osteoporosis.

Zhang X, Li SW, Wu JF, Dong CL, Zheng CX, Zhang YP, Du J.

Gynecol Endocrinol. 2010 Feb;26(2):76-80. doi: 10.3109/09513590903184159.

PMID:
19672742
2.

Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.

Fujita T, Fujii Y, Miyauchi A, Takagi Y.

J Bone Miner Metab. 1999;17(4):289-95.

PMID:
10575594
3.

Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.

Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone Multicenter European Fracture Study.

JAMA. 2001 Mar 21;285(11):1482-8.

PMID:
11255425
4.

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.

Gennari C, Adami S, Agnusdei D, Bufalíno L, Cervetti R, Crepaldi G, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani S, Passeri M, Serni U, Vecchiet L.

Calcif Tissue Int. 1997;61 Suppl 1:S19-22.

PMID:
9263612
5.

[Effect of milk product with soy isoflavones on quality of life and bone metabolism in postmenopausal Spanish women: randomized trial].

García-Martín A, Quesada Charneco M, Alvárez Guisado A, Jiménez Moleón JJ, Fonollá Joya J, Muñoz-Torres M.

Med Clin (Barc). 2012 Feb 4;138(2):47-51. doi: 10.1016/j.medcli.2011.04.033. Epub 2011 Oct 22. Spanish.

PMID:
22024564
6.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
7.

A calcium-collagen chelate dietary supplement attenuates bone loss in postmenopausal women with osteopenia: a randomized controlled trial.

Elam ML, Johnson SA, Hooshmand S, Feresin RG, Payton ME, Gu J, Arjmandi BH.

J Med Food. 2015 Mar;18(3):324-31. doi: 10.1089/jmf.2014.0100. Epub 2014 Oct 14.

PMID:
25314004
8.

Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.

Melis GB, Paoletti AM, Bartolini R, Tosti Balducci M, Massi GB, Bruni V, Becorpi A, Ottanelli S, Fioretti P, Gambacciani M, et al.

Bone Miner. 1992 Oct;19 Suppl 1:S49-56.

PMID:
1422321
9.
10.
11.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
12.

Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.

Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F.

J Bone Miner Res. 2002 Oct;17(10):1904-12.

13.

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.

Osteoporos Int. 1999;10(4):330-6. Erratum in: Osteoporos Int 1999;10(5):433.

PMID:
10692984
14.

Design for an ipriflavone multicenter European fracture study.

Reginster JY, Bufalino L, Christiansen C, Devogelaer JP, Gennari C, Riis BJ, Roux C.

Calcif Tissue Int. 1997;61 Suppl 1:S28-32.

PMID:
9263614
15.

The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women.

Celik E, Guzel S, Abali R, Guzelant AY, Celik Guzel E, Kuçukyalcin V.

Minerva Med. 2013 Oct;104(5):497-504.

PMID:
24101107
16.

Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.

Wang SX, Li H.

Chin Med J (Engl). 2008 Jul 20;121(14):1280-4.

PMID:
18713548
17.
18.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11. Epub 2005 Jul 18.

19.

Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.

Hannon R, Blumsohn A, Naylor K, Eastell R.

J Bone Miner Res. 1998 Jul;13(7):1124-33.

20.

Efficacy of ipriflavone in established osteoporosis and long-term safety.

Agnusdei D, Bufalino L.

Calcif Tissue Int. 1997;61 Suppl 1:S23-7.

PMID:
9263613

Supplemental Content

Support Center